P-21

P-21

P-21 (P021, Ac-DGGLAG-NH₂) — adamantylated CNTF-mimetic tetrapeptide; LIF pathway antagonist and BDNF amplifier with documented cognitive rescue, neurogenesis, and tau-reduction in Alzheimer’s, Down syndrome, and TBI mouse models.

Description

Summary Abstract

P-21 (P021; Peptide 021; Ac-DGGLAG-NH2; Acetyl-Asp-Gly-Gly-Leu-Adamantylglycine-amide; MW ~578.3 g/mol) is a rationally designed synthetic tetrapeptide mimetic of the neurogenic epitope of human Ciliary Neurotrophic Factor (CNTF), specifically corresponding to residues 148–151 (Epitope 6) of the native protein. Engineered by Dr. Khalid Iqbal and colleagues, P-21 overcomes the systemic liabilities of full-length recombinant CNTF (severe cachexia, anorexia, and rapid immunogenic neutralization) by using only the six-amino-acid sequence responsible for neurogenic signaling, with a C-terminal adamantane modification that confers proteolytic resistance (plasma t½ >3 h vs. 2.9 min for rH-CNTF) and blood-brain barrier permeability via lipophilic passive diffusion. P-21 acts as a competitive inhibitor of Leukemia Inhibitory Factor (LIF) signaling — suppressing STAT3 phosphorylation and shifting neural progenitor cell fate from astrogliosis toward neurogenesis — while robustly upregulating BDNF, which activates TrkB → PI3K/Akt → CREB cascades to drive synaptic plasticity, neuronal survival, and GSK-3β inhibition (reducing tau hyperphosphorylation). In 3xTg-AD mice, P-21 reversed established tau and amyloid pathology even after disease onset. In the Ts65Dn Down syndrome model, it rescued neurogenesis and developmental cognitive milestones. In TBI models, it directed injury-induced progenitor-cell differentiation toward functional neurons rather than glial scar. Phanes Biotech is advancing P-21 (as PB021) toward clinical development with completed acute toxicity studies showing safety up to 550× the therapeutic dose.

Clinical Indications

P-21’s LIF antagonism and BDNF amplification address foundational neurogenic failure across multiple conditions:

  • Alzheimer’s Disease (Disease Modification): In 3xTg-AD mice with established pathology (9–12 months): reduced phospho-tau at AT8/PHF-1/12E8 epitopes, reduced soluble Aβ40/42, restored neurogenesis in dentate gyrus to wild-type levels, and rescued Morris Water Maze and Novel Object Recognition performance.
  • Down Syndrome / Neurodevelopmental Deficits: In Ts65Dn mice: rescued neurogenesis during prenatal/early postnatal administration, advanced developmental milestones, and produced lasting hippocampal cognitive improvements in adult animals.
  • Traumatic Brain Injury: In TBI rodent models: stimulated progenitor-cell proliferation in the subgranular zone and directed differentiation toward mature NeuN-positive neurons rather than astrocytic scar, enhancing neural-circuit repair.
  • Age-Related Macular Degeneration (AMD): In aged and 3xTg-AD mice: systemic P-21 reduced RPE lipofuscin and Aβ accumulation, decreased microglial activation, and preserved photoreceptor density — positioning it as a potential candidate for dry AMD.
  • Cognitive Enhancement in Healthy Subjects: P-21 improved spatial reference memory and short-term memory in wild-type C57BL/6 mice, suggesting BDNF-mediated augmentation of baseline synaptic plasticity beyond deficit repair.

Contraindications

  • Active Malignancy: LIF modulation is contextually complex; LIF can act as both tumor promoter and suppressor depending on cancer type. 18-month rodent carcinogenicity studies showed no tumor induction, but theoretical risk in active malignancy contexts cannot be excluded.
  • Pregnancy (Developmental Risk): LIF/CNTF pathways are essential for embryonic morphogenesis; modulation during pregnancy carries unpredictable developmental risk.
  • Active Autoimmune Neuroinflammation: The shift from astrogliosis to neurogenesis may alter inflammatory microenvironments in ways that are not fully characterized in active CNS autoimmune conditions.

Mechanism of Action (MOA)

P-21 functions as a neurogenic switch, releasing progenitor-cell proliferation from inhibitory constraints while simultaneously amplifying pro-survival and plasticity signals:

LIF / STAT3 Competitive Inhibition

In the adult brain, Leukemia Inhibitory Factor (LIF) maintains neural progenitor cells (NPCs) in a quiescent state and promotes astrogliosis over neurogenesis via JAK/STAT3 phosphorylation. P-21 competitively inhibits LIF signaling — blocking STAT3 phosphorylation and releasing the proliferative brake on dentate-gyrus NPCs. This shifts the cellular outcome from glial scar formation toward functional neurogenesis and structural brain repair.

BDNF Amplification Cascade

P-21 robustly upregulates both BDNF mRNA and BDNF protein in the hippocampus and cortex. Increased BDNF activates TrkB receptor dimerization → PI3K/Akt phosphorylation → CREB transcription, driving expression of synaptic-structure genes (synapsin I, MAP2) and anti-apoptotic programs. This BDNF amplification cascade is considered the primary downstream driver of P-21’s therapeutic effects on synaptic plasticity and neuronal survival.

GSK-3β Inhibition → Tau Pathology Reduction

PI3K/Akt activation downstream of TrkB/BDNF leads to Akt-mediated phosphorylation of GSK-3β at Serine-9, inhibiting the tau kinase. In AD, GSK-3β overactivity hyperphosphorylates tau, causing microtubule detachment and neurofibrillary-tangle formation. P-21 treatment reduces phospho-tau at multiple epitopes (AT8, PHF-1, 12E8) even in mice with established 9-month pathology, demonstrating potential for tau reversal rather than mere prevention.

ADAM10 Upregulation → Non-Amyloidogenic APP Processing

BDNF signaling driven by P-21 enhances the expression and membrane trafficking of ADAM10 (α-secretase), which cleaves amyloid precursor protein (APP) within the Aβ domain. This α-secretase cleavage is mutually exclusive with β-secretase cleavage that generates Aβ peptides, instead producing soluble sAPPα — a neuroprotective metabolite. P-21 thereby shifts APP processing from the amyloidogenic to the non-amyloidogenic pathway, reducing new plaque formation.

Key Features & Specifications

P-21 addresses the clinical failures of both full-length CNTF and heterogeneous peptide extracts:

Adamantylated — BBB-permeable, protease-resistant
No cachexia or anorexia (lacks CNTF hypothalamic-binding domain)
Negligible immunogenicity (sub-threshold peptide size)
Reverses established tau and amyloid pathology
Safe to 550× therapeutic dose (acute toxicology)
10 MG lyophilized (SKU P-060)

Chemical Analysis

Property Specification Reference Data
Sequence Ac-Asp-Gly-Gly-Leu-Adamantylglycine-NH2 (Ac-DGGLAG-NH2; adamantane moiety attached to C-terminal glycine)
CAS Number Not formally registered; investigational compound (Phanes Biotech designation PB021)
Molecular Weight ~578.3 g/mol
PubChem CID Not assigned (investigational new chemical entity)
Synonyms P021, Peptide 021, PB021, P21 CNTF mimetic, Ac-DGGLAG-NH₂
Form / Variation 10 MG Lyophilized (SKU P-060)

Storage, Safety, and Handling

Storage Protocol

Store lyophilized P-21 at −20 °C or below, desiccated and protected from light. Reconstitute in sterile bacteriostatic water or PBS at the concentration specified on the certificate of analysis. Immediately aliquot reconstituted peptide and freeze at −80 °C; avoid repeated freeze-thaw cycles. Subcutaneous or intranasal delivery routes align with preclinical administration methods.

Handling & Compliance

Handle with standard laboratory PPE. Acute toxicity studies confirmed safety at doses 550-fold above the therapeutic range in animal models; no cachexia, anorexia, or weight loss observed at any dose tested — in stark contrast to full-length rH-CNTF. Negligible immunogenicity due to sub-threshold peptide size (6 amino acids including modification). P-21 is an investigational compound (Phanes Biotech Pre-IND status); no regulatory agency has granted marketing authorization. All research protocols should comply with institutional oversight requirements.